Abstract:Introduction In 2017, the European LeukemiaNet (ELN) stratified AML patients into 3 risk groups based on the presence or absence of specific chromosome abnormalities and selected gene mutations.1 However, some studies have suggested that the prognosis or CR rates are heterozygous in the 2017 ELN favorable group depending on the specific co-existing mutations.2 Although they were not included in 2017 ELN due to an insufficient accumulation of evidence, some mutations involved in DNA methylation, including DNMT3A and IDH1/2, revealed adverse effects in AML prognosis.1,3-5 The goal of the current study was to evaluate how the DNA methylation regulatory (DNA-MR) gene mutations may impact the outcomes of AML patients categorized as favorable risk according to the ELN risk stratification. Methodology All AML patients diagnosed at our institution from 2017-08-01 to 2020-03-10 were reviewed for this study. All patient samples were tested for morphologic evaluation, flow cytometry immunophenotyping, conventional karyotyping and next generation sequencing using a target panel covering 53 AML related genes, including DNA-MR genes: DNMT3A, TET2, IDH1, IDH2 or SETBP1. All AML cases were then classified based on 2016 WHO classification of AML, and risk groups were assigned using the ELN risk stratification scheme. Treatment-related AML patients were excluded. Afterward, patients aged 18 - 75 who underwent intensive induction chemotherapy were included for survival and response rate analysis, since the ELN risk stratification scheme was built primarily based on this population. The patients were divided into 4 groups: 1) ELN favorable with at least one mutation of DNA-MR genes 2) ELN favorable without DNA-MR gene mutations, 3) ELN intermediate, and 4) ELN adverse. The log-rank test was used to compare the OS and RFS difference between 4 groups. CR rates were compared by chi-square test or Fischer's exact test. Bonferroni adjustment was performed to prevent type I error at a level of 0.8%. Two-tailed statistical significance at a level of 5% was used for statistical analysis. All analyses were performed using SAS 9.4 (SAS Institute, Cary, NC) and R RStudio Team (2020). Results A total of 125 patients were qualified for the study and the median follow-up for the cohort was 404 days. Among ELN favorable risk patients (n = 45), the mutations of DNA-MR genes occurred in 19 (42.2%) patients: DNMT3A, 20% (9/45); IDH2, 13% (6/45); TET2, 11% (5/45); IDH1, 9% (4/25). This led to 19, 26, 38, and 42 patients classified as Groups 1, 2, 3 and 4 respectively. In contrast, DNA-MR gene mutations were less common in ELN intermediate and adverse groups, and occurred in 34.2% (13/38) and 19.0% (8/42) respectively. Figure 1 shows OS and RFS of 4 groups by Kaplan-Myer Curve. The median OS for groups 1, 2, 3 and 4 were 306, not reached, 987, and 422 days, respectively. There was significant difference in OS between ELN favorable with versus without DNA-MR gene mutations (Group 1 vs 2; p-value: 0.0002). There was no significant OS difference between ELN favor with DNA-MR gene mutations versus ELN intermediate (Group 1 vs 3; p-value: 0.0921) or versus ELN adverse group (Group 1 vs 4; p-value: 0.9455). The median RFS for groups 1, 2, 3 and 4 were 511, not reached, 240, and 305 days. There was significant difference in RFS between ELN favorable with versus without DNA-MR gene mutations (Group 1 vs 2: adjusted p-value:0.0089). There were no significant RFS differences between ELN favorable with DNA-MR gene mutations versus intermediate (Group 1 vs 3; p value: 0.2304) or versus adverse group (Groups 1 vs 4; p-value: 0.6661). CR rate of groups 1, 2, 3 and 4 were 79%, 96%, 82% and 57% respectively. The CR rate of Group 1 was not statistically significantly different from CR rate of Group 2, 3, and 4. Further subgroup analysis revealed that the co-existing DNA-MR gene mutations did not impact OS and RFS in ELN intermediate and adverse groups. Discussion Our results indicate that mutations of DNA methylation regulatory genes are common in AML patients with ELN favorable risk. Furthermore, these mutations lead to poor prognosis of this subgroup of patients considered favorable risk, with OS and RFS similar to that of patients in the ELN adverse risk group. Currently this subgroup of patients does not receive upfront stem cell transplant due to the favorable outcome and thus may not receive adequate treatment. Further studies are warranted to confirm our observations. Disclosures No relevant conflicts of interest to declare.

The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia

A Risk Score Combined Clinical and Molecular Profiles Identifies a High-Risk Subgroup Within AML1-ETO-Positive Acute Myeloid Leukemia

MiR-362-5p As a Novel Prognostic Predictor of Cytogenetically Normal Acute Myeloid Leukemia

Application of SENP-1, HIF-1α and VEGF Gene Expressions in Prognostic Prediction for Normal Karyotypic Acute Leukemia Patients with NPM1 + and FLT3-ITD - .

The Expression Level of Neuronal Calcium Sensor 1 Can Predict the Prognosis of Cytogenetically Normal AML

Prognostic Role of ACTL10 in Cytogenetic Normal Acute Myeloid Leukemia

Predictive Value of Unmethylated RASSF1A on Disease Progression in Non-Small Cell Lung Cancer Patients Receiving Pemetrexed-Based Chemotherapy

High Expression of CLEC11A Predicts Favorable Prognosis in Acute Myeloid Leukemia

Identification of Potential Novel Prognosis-Related Genes Through Transcriptome Sequencing, Bioinformatics Analysis, and Clinical Validation in Acute Myeloid Leukemia

Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia.

High expression of ARHGEF5 predicts unfavorable prognosis in acute myeloid leukemia

Novel Prognostic Genes and Subclasses of Acute Myeloid Leukemia Revealed by Survival Analysis of Gene Expression Data.

High Expression of LOC541471, GDAP1, SOD1, and STK25 is Associated with Poor Overall Survival of Patients with Acute Myeloid Leukemia.

Establishment and validation of a gene mutation-based risk model for predicting prognosis and therapy response in acute myeloid leukemia

High trophinin-associated protein expression predicts good survival in acute myeloid leukemia with normal cytogenetics

NDRG2 and TLR7 As Novel DNA Methylation Prognostic Signatures for Acute Myelocytic Leukemia.

Adverse Impact of Mutations in DNA Methylation Regulatory Genes on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group

An mRNA expression signature for prognostication in de novo acute myeloid leukemia patients with normal karyotype

P519: RISK STRATIFICATION BY NOMOGRAM SCORING SYSTEM OF NPM1-MUTATED CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIALEUKAEMIA BASED ON A MULTI-GENE PANEL

Gene coexpression network analysis revealed biomarkers correlated with blast cells and survival in acute myeloid leukemia

Ctnna1 Hypermethylation, A Frequent Event In Acute Myeloid Leukemia, Is Independently Associated With An Adverse Outcome